
Galectin Therapeutics Inc.: shareholders and insiders
Price
$2.69
November 20, 2026Market cap $271M
What Ploutos Investor adds for Galectin Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from 2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Aug 4, 2026, from their own Form 4 filings.
Bought on the market
$22.9K
2 people
Sold on the market
$4.6M
6 people
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan61%
- The rest39%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $810 by 1 person·sold $1.3M by 4 people
- 2025: bought $22.1K by 2 people, sold $3.3M by 5 people
- 2026: bought $810 by 1 person, sold $1.3M by 4 people
- Jul 31, 2026Richard E UihleinDirectorKind
- Jul 31, 2026Richard E UihleinDirectorKind
- Jul 14, 2026Khurram JamilChief Medical OfficerKind10b5-1
- Jul 14, 2026Khurram JamilChief Medical OfficerKind10b5-1
- Jun 29, 2026Harold H. ShlevinDirectorKind10b5-1
- Jun 29, 2026Harold H. ShlevinDirectorKind10b5-1
- Jun 29, 2026Khurram JamilChief Medical OfficerKind10b5-1
- Jun 29, 2026Khurram JamilChief Medical OfficerKind10b5-1
- Jun 26, 2026Harold H. ShlevinDirectorKind10b5-1
- Jun 26, 2026Harold H. ShlevinDirectorKind10b5-1
- Jun 26, 2026Khurram JamilChief Medical OfficerKind10b5-1
- Jun 26, 2026Khurram JamilChief Medical OfficerKind10b5-1
- Jun 26, 2026Khurram JamilChief Medical OfficerKind10b5-1
- Jun 26, 2026Khurram JamilChief Medical OfficerKind10b5-1
- Jun 23, 2026Khurram JamilChief Medical OfficerKind10b5-1
- Jun 23, 2026Khurram JamilChief Medical OfficerKind10b5-1
- May 26, 2026Khurram JamilChief Medical OfficerKind10b5-1
- May 26, 2026Khurram JamilChief Medical OfficerKind10b5-1
- Feb 6, 2026Kary EldredKind
- Jan 6, 2026Khurram JamilChief Medical OfficerKind10b5-1
- Jan 6, 2026Jack W CallicuttChief Financial OfficerKind10b5-1
- Jan 6, 2026Joel LewisPresident and CEOKind10b5-1
- Jan 5, 2026Khurram JamilChief Medical OfficerKind10b5-1
- Jan 5, 2026Jack W CallicuttChief Financial OfficerKind10b5-1
- Jan 5, 2026Joel LewisPresident and CEOKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | Richard E UihleinDirector | 31.83M | $3.00 | $95M | Form 4 | |
| Jul 31, 2026 | Richard E UihleinDirector | 2.55M | $4.05 | $10M | Form 4 | |
| Jul 14, 2026 | Khurram JamilChief Medical Officer | 10b5-1 | 16.3K | $3.04 | $49.4K | Form 4 |
| Jul 14, 2026 | Khurram JamilChief Medical Officer | 10b5-1 | 16.3K | $5.13 | $83.3K | Form 4 |
| Jun 29, 2026 | Harold H. ShlevinDirector | 10b5-1 | 22.3K | $1.23 | $27.4K | Form 4 |
| Jun 29, 2026 | Harold H. ShlevinDirector | 10b5-1 | 22.3K | $5.04 | $112.2K | Form 4 |
| Jun 29, 2026 | Khurram JamilChief Medical Officer | 10b5-1 | 47.5K | $2.50 | $118.7K | Form 4 |
| Jun 29, 2026 | Khurram JamilChief Medical Officer | 10b5-1 | 47.5K | $5.04 | $239.2K | Form 4 |
| Jun 26, 2026 | Harold H. ShlevinDirector | 10b5-1 | 7,732 | $1.23 | $9.5K | Form 4 |
| Jun 26, 2026 | Harold H. ShlevinDirector | 10b5-1 | 7,732 | $5.00 | $38.7K | Form 4 |
| Jun 26, 2026 | Khurram JamilChief Medical Officer | 10b5-1 | 2,037 | $2.20 | $4.5K | Form 4 |
| Jun 26, 2026 | Khurram JamilChief Medical Officer | 10b5-1 | 2,037 | $5.00 | $10.2K | Form 4 |
| Jun 26, 2026 | Khurram JamilChief Medical Officer | 10b5-1 | 2,533 | $2.50 | $6.3K | Form 4 |
| Jun 26, 2026 | Khurram JamilChief Medical Officer | 10b5-1 | 2,533 | $5.00 | $12.7K | Form 4 |
| Jun 23, 2026 | Khurram JamilChief Medical Officer | 10b5-1 | 7,557 | $1.23 | $9.3K | Form 4 |
| Jun 23, 2026 | Khurram JamilChief Medical Officer | 10b5-1 | 7,557 | $3.14 | $23.7K | Form 4 |
| May 26, 2026 | Khurram JamilChief Medical Officer | 10b5-1 | 568 | $1.23 | $699 | Form 4 |
| May 26, 2026 | Khurram JamilChief Medical Officer | 10b5-1 | 568 | $3.10 | $1.8K | Form 4 |
| Feb 6, 2026 | Kary Eldred | 300 | $2.70 | $810 | Form 4 | |
| Jan 6, 2026 | Khurram JamilChief Medical Officer | 10b5-1 | 21.4K | $3.65 | $78.3K | Form 4 |
| Jan 6, 2026 | Jack W CallicuttChief Financial Officer | 10b5-1 | 20.4K | $3.67 | $74.7K | Form 4 |
| Jan 6, 2026 | Joel LewisPresident and CEO | 10b5-1 | 37.7K | $3.58 | $135.0K | Form 4 |
| Jan 5, 2026 | Khurram JamilChief Medical Officer | 10b5-1 | 25.5K | $3.90 | $99.4K | Form 4 |
| Jan 5, 2026 | Jack W CallicuttChief Financial Officer | 10b5-1 | 25.7K | $3.90 | $100.4K | Form 4 |
| Jan 5, 2026 | Joel LewisPresident and CEO | 10b5-1 | 27.7K | $3.91 | $108.4K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 28, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by GALT's officers and directors from 2006 up to November 21, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Richard E. UihleinShare of class49.3%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Richard E. Uihlein | 49.3% | 54.67M | Aug 4, 2026 | 13D/A |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Richard E. Uihlein49.3%From the filing of Aug 4, 2026
The Shares were acquired for investment purposes and were not acquired with the purpose or effect of changing or influencing control of the Company.
From the filing of Aug 4, 2026
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter-4.1%
- Millennium Mgmt (Englander)In the quarter
- Renaissance TechnologiesIn the quarter+155%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 190.5K | -4.1% | $700.0K | 0.00% |
| Millennium Mgmt (Englander) | – | – | 0.00% | |
| Renaissance Technologies | 110.6K | +155% | $400.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 9.05% of its shares outstanding were held short, -0.8% since the report before.
- Shares held short
- 9.13M
- 9.05%
- Since the report before9.21M on Sep 30, 2026
- -0.8%
- 40.0
- 228.4K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 100%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 1.95M
- Nov 15, 2023: Shares held short 1.95M
- Nov 30, 2023: Shares held short 2.11M
- Dec 15, 2023: Shares held short 2.13M
- Dec 29, 2023: Shares held short 2.11M
- Jan 12, 2024: Shares held short 2.09M
- Jan 31, 2024: Shares held short 2.08M
- Feb 15, 2024: Shares held short 2.08M
- Feb 29, 2024: Shares held short 2.10M
- Mar 15, 2024: Shares held short 2.14M
- Mar 28, 2024: Shares held short 2.25M
- Apr 15, 2024: Shares held short 2.74M
- Apr 30, 2024: Shares held short 3.12M
- May 15, 2024: Shares held short 3.73M
- May 31, 2024: Shares held short 3.82M
- Jun 14, 2024: Shares held short 3.95M
- Jun 28, 2024: Shares held short 4.01M
- Jul 15, 2024: Shares held short 4.57M
- Jul 31, 2024: Shares held short 4.71M
- Aug 15, 2024: Shares held short 5.01M
- Aug 30, 2024: Shares held short 5.06M
- Sep 13, 2024: Shares held short 5.26M
- Sep 30, 2024: Shares held short 5.38M
- Oct 15, 2024: Shares held short 5.46M
- Oct 31, 2024: Shares held short 5.52M
- Nov 15, 2024: Shares held short 5.70M
- Nov 29, 2024: Shares held short 5.86M
- Dec 13, 2024: Shares held short 8.27M
- Dec 31, 2024: Shares held short 8.04M
- Jan 15, 2025: Shares held short 8.16M
- Jan 31, 2025: Shares held short 7.98M
- Feb 14, 2025: Shares held short 7.72M
- Feb 28, 2025: Shares held short 8.12M
- Mar 14, 2025: Shares held short 8.15M
- Mar 31, 2025: Shares held short 7.89M
- Apr 15, 2025: Shares held short 8.36M
- Apr 30, 2025: Shares held short 8.47M
- May 15, 2025: Shares held short 8.67M
- May 30, 2025: Shares held short 8.90M
- Jun 13, 2025: Shares held short 8.95M
- Jun 30, 2025: Shares held short 7.79M
- Jul 15, 2025: Shares held short 7.70M
- Jul 31, 2025: Shares held short 7.71M
- Aug 15, 2025: Shares held short 7.96M
- Aug 29, 2025: Shares held short 7.99M
- Sep 15, 2025: Shares held short 8.05M
- Sep 30, 2025: Shares held short 8.21M
- Oct 15, 2025: Shares held short 8.39M
- Oct 31, 2025: Shares held short 6.90M
- Nov 14, 2025: Shares held short 6.76M
- Nov 28, 2025: Shares held short 6.82M
- Dec 15, 2025: Shares held short 5.95M
- Dec 31, 2025: Shares held short 4.90M
- Jan 15, 2026: Shares held short 4.75M
- Jan 30, 2026: Shares held short 4.80M
- Feb 13, 2026: Shares held short 5.09M
- Feb 27, 2026: Shares held short 5.17M
- Mar 13, 2026: Shares held short 6.57M
- Mar 31, 2026: Shares held short 6.80M
- Apr 15, 2026: Shares held short 7.46M
- Apr 30, 2026: Shares held short 7.39M
- May 15, 2026: Shares held short 7.36M
- May 29, 2026: Shares held short 7.66M
- Jun 15, 2026: Shares held short 7.87M
- Jun 30, 2026: Shares held short 8.97M
- Jul 15, 2026: Shares held short 8.49M
- Jul 31, 2026: Shares held short 8.70M
- Aug 14, 2026: Shares held short 9.00M
- Aug 31, 2026: Shares held short 9.08M
- Sep 15, 2026: Shares held short 9.34M
- Sep 30, 2026: Shares held short 9.21M
- Oct 15, 2026: Shares held short 9.13M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading49.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 49.2% of the shares in the reported trades were short sales, against 48.7% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 49.2%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 48.7%
- Change
- +0.5 pts
- Short sales a dayon average, of 93.1K shares
- 45.8K
- More than atof 3,666 US-listed companies, same days
- 46%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 40.7%
- Oct 15, 2026: Short sales 46.2%
- Oct 16, 2026: Short sales 55.6%
- Oct 19, 2026: Short sales 40%
- Oct 20, 2026: Short sales 48.3%
- Oct 21, 2026: Short sales 51.4%
- Oct 22, 2026: Short sales 28.7%
- Oct 23, 2026: Short sales 44.2%
- Oct 26, 2026: Short sales 52.3%
- Oct 27, 2026: Short sales 57.1%
- Oct 28, 2026: Short sales 46.1%
- Oct 29, 2026: Short sales 75.8%
- Oct 30, 2026: Short sales 50.6%
- Nov 2, 2026: Short sales 41.2%
- Nov 3, 2026: Short sales 44.2%
- Nov 4, 2026: Short sales 50.1%
- Nov 5, 2026: Short sales 44.1%
- Nov 6, 2026: Short sales 43.2%
- Nov 9, 2026: Short sales 53.7%
- Nov 10, 2026: Short sales 63.1%
- Nov 11, 2026: Short sales 61.1%
- Nov 12, 2026: Short sales 38.8%
- Nov 13, 2026: Short sales 68.5%
- Nov 16, 2026: Short sales 42.4%
- Nov 17, 2026: Short sales 55.1%
- Nov 18, 2026: Short sales 47.1%
- Nov 19, 2026: Short sales 35.8%
- Nov 20, 2026: Short sales 57.7%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Richard E UihleinDirectorDirectly44.74M
- James C CzirrTenPercentOwnerDirectly5.61M
- 10X Fund, L.P.TenPercentOwnerDirectly–
- 10X Capital Management, LLCTenPercentOwnerDirectly5.67M
- Joel LewisPresident and CEODirectly832.6K
- Kevin D FreemanDirectorDirectly55.3K
- Kary EldredDirectorDirectly65.7K
- Richard A. Zordani Jr.DirectorDirectly42.1K
- Jack W CallicuttChief Financial OfficerDirectly7,614
- Harold H. ShlevinDirectorDirectly6,500
- Khurram JamilChief Medical OfficerDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Richard E UihleinDirector | 44.74M | – | Jul 31, 2026 | Form 4 |
| James C CzirrTenPercentOwner | 5.61M | 5.92M | Dec 16, 2025 | Form 4 |
| 10X Fund, L.P.TenPercentOwner | – | 5.92M | Apr 23, 2024 | Form 4 |
| 10X Capital Management, LLCTenPercentOwner | 5.67M | – | Dec 3, 2025 | Form 4 |
| Joel LewisPresident and CEO | 832.6K | 2,000 | Jan 6, 2026 | Form 4 |
| Kevin D FreemanDirector | 55.3K | 80.0K | Dec 23, 2025 | Form 4 |
| Kary EldredDirector | 65.7K | – | Feb 6, 2026 | Form 4 |
| Richard A. Zordani Jr.Director | 42.1K | 2,000 | Dec 24, 2024 | Form 4 |
| Jack W CallicuttChief Financial Officer | 7,614 | – | Jan 6, 2026 | Form 4 |
| Harold H. ShlevinDirector | 6,500 | – | Jun 29, 2026 | Form 4 |
| Khurram JamilChief Medical Officer | – | – | Jul 14, 2026 | Form 4 |
A lower bound: it counts only the 11 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.05%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.01%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.00%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
7 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 84
- Q4 2025: Managers 98
- Q1 2026: Managers 99
- Q2 2026: Managers 99
Institutional investors by quarter
The fund managers holding GALT, quarter by quarter, from Q2 2013 to Q2 2025, 49 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 99 managers held 16.04M shares, worth $74M. During the quarter 19 opened a position, 20 closed one, 29 added and 23 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+274%
- Vanguard Capital ManagementIn the quarter+10%
- Geode Capital ManagementIn the quarter+114%
- Osaic HoldingsIn the quarter+7.2%
- Marshall WaceIn the quarter-32%
- Wealthspire AdvisorsIn the quarter
- State StreetIn the quarter+120%
- Commonwealth Equity ServicesIn the quarter+11%
- Northern TrustIn the quarter+196%
- Vanguard Fiduciary TrustIn the quarter+20%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 2.99M | +274% | $14M |
| Vanguard Capital Management | 2.17M | +10% | $10M |
| Geode Capital Management | 1.31M | +114% | $6.1M |
| Osaic Holdings | 1.20M | +7.2% | $5.6M |
| Marshall Wace | 831.0K | -32% | $3.9M |
| Wealthspire Advisors | 721.8K | $3.3M | |
| State Street | 567.8K | +120% | $2.6M |
| Commonwealth Equity Services | 407.1K | +11% | $1.9M |
| Northern Trust | 386.5K | +196% | $1.8M |
| Vanguard Fiduciary Trust | 366.5K | +20% | $1.7M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Galectin Therapeutics's filings show?
Who buys and sells is one part of Galectin Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have GALT's insiders bought or sold?
From May 28, 2026 to Aug 4, 2026 Galectin Therapeutics's insiders bought 0 and sold $521.7K of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold GALT?
3 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $700.0K.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.